Addressing MPs, Reeves said: "I recognise that households who use heating oil face unique challenges, and so I have asked the Financial Secretary to the Treasury to lead discussions with officials and with rural and Northern Irish MPs to explore further action that we can take."

美股三大指数集体收涨 2026-03-10 04:02:25 来源： 同花顺7x24快讯 分享 文章提及标的 标准普尔500指数 -- 亚马逊 -- 苹果 -- 谷歌C -- 道琼斯工业平均指数 -- 英伟达 -- 美股三大指数集体收涨，道指（DJI）涨0.5%，纳指涨1.38%，标普500（SPX）指数涨0.83%。英伟达（NVDA）涨超2%，苹果（AAPL）涨近1%，谷歌（GOOG）涨超2%，亚马逊（AMZN）、微软（MSFT）微涨，博通（AVGO）涨超4%。

Kemi may be all in favour, but at least economic realpolitik is forcing her to take a slightly different tack There have been any number of opportunities for people to decide they wanted no part of America’s war with Iran. The first was after the US had launched its first wave of strikes. To be fair, this was the moment Keir Starmer and most of the UK reckoned enough was enough and that our involvement would be limited to defensive strikes only. You couldn’t really fault the logic. Did the UK really want to be part of a war that was illegal in most versions of international law and for which the Americans had no clear vision of how it might end? Other than Donald Trump gets bored and lets everyone else clear up his mess. Like a baby. Nor was the UK’s track record of wars in the 21st century any source of pride. Iraq, Afghanistan and Libya had all been in chaos. Iran was shaping up the same way. So Starmer decided to sit this one out. Applying the doctor’s principle of ”first, do no harm”. Continue reading...

- Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain cancer treatment - - Multiple meaningful milestones targeted in the coming months, including completion of patient recruitment in the U.S. pivotal ReSTART skin cancer trial, in the U.S. pilot IMPACT pancreatic cancer trial, and in the U.S. recurrent glioblastoma multiforme feasibility trial - - $76.9 million in cash, cash equivalents & deposits provides continued balance sheet strength for clinical advancement and commercial preparation - JERUSALEM, March 09, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, reported full year 2025 financial results and provided a corporate update. "The pace of progress at Alpha Tau today is unlike anything we’ve ever seen before," said Alpha Tau Chief Executive Officer Uzi Sofer. “With a slew of meaningful announcements in the past few months, culminating most recently with our receipt of marketing approval in Japan, our first outside of Israel, and with multiple meaningful milestones targeted for the coming months, we remain laser focused on execution. Clinical trial progress remains our highest priority, with an astounding five clinical trials approved in parallel in the U.S. At the same time, we continue to build out our manufacturing capabilities in New Hampshire as well as our pre-commercial preparations, while entertaining multiple tracks of strategic dialogue with partners who show increasing excitement about the ever-expanding prospects for Alpha DaRT.” Recent Corporate Highlights: Commercial-Scale U.S. Manufacturing Milestone: In October, Alpha Tau announced the receipt of a radioactive material license for its New Hampshire manufacturing facility, its first commercial-scale facility...

葡萄牙新總統塞古羅宣誓就職，國家主席習近平致賀電，稱雙邊關係健康穩定發展。 塞古羅周一在首都里斯本到議會出席宣誓就職。葡萄牙總理蒙特內格羅、西班牙國王費利佩六世亦在場。 領導中左翼社會黨的塞古羅，指任內執政重點會是改善公共醫療體系、住房、人口老齡化等領域，並努力促進經濟增長。 國家主席習近平向他致賀電指中葡兩國建交47年來，雙邊關係始終健康穩定發展，堅持相互尊重、相互支持、運用政治智慧妥善解決澳門問題。習近平強調，高度重視中葡關係發展，願同塞古羅一同加強戰略溝通，促進高質量合作。

Oracle Corporation Class Action: Levi & Korsinsky Reminds Oracle Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 – ORCL marketscreener.com

塞诺龙制药公司的股价在获得美国食品药品监督管理局的有利认定后飙升了47.71%，这提升了公司前景和投资者信心。 财务概览 从财务指标的核心来看，塞诺龙制药公司是一个独特的存在。尽管最近一个季度的亏损略高于预期，但仍取得了显著进展。该公司在其癫痫和神经精神药物azetukalner的多项三期研究中成功推进，展现了其韧性。在短期财务逆境中，这一进展如同一线希望。 深入来看，塞诺龙的季度营收约为750万美元。然而，实现盈利的道路依然充满挑战，其息税前利润率为负，去年累计净亏损超过1亿美元。尽管如此，凭借近5.5亿美元的强劲现金储备，塞诺龙拥有为当前和未来计划提供资金的流动性。 从市场角度看，其市销率高达465.2倍，表明可能存在估值过高。然而，潜在投资者并未却步。其丰富的产品管线，尤其是X-TOLE2试验，为隧道尽头带来了一丝曙光，特别是对于愿意经受早期动荡以换取长期收益的利益相关者而言。 预期的市场影响 基于当前情况，塞诺龙的未来可谓雄心勃勃。Stifel和Wolfe Research的分析师都对塞诺龙的未来寄予厚望，赞扬其在癫痫疗法领域的创新投入。金融界的知名人士通过调整目标价和充满信心的认可，激发了投资者的热情，并提升了市场兴趣。 其产品线中一个全面的重磅药物开发项目标志着重大进展，这不仅可能提升公司在科学界的地位，还可能大幅增加其市值。尽管前进道路上存在明显的障碍——从临床试验的不利因素到运营亏损——但受有前景的试验结果和策略性分析师背书的鼓舞，交易员们仍对其未来前景持乐观态度。 追求突破性疗法的不懈战略动力为患者和投资者都带来了希望。所有人的目光都集中在即将发布的重要试验数据上，这些数据在生物制药领域被视为可能改变游戏规则的关键信息。 责任编辑：张俊 SF065

NEW YORK and WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it has commenced an underwritten public offering of $400 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Dianthus expects to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares of common stock at the public offering price, less underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Dianthus.

WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced an inducement grant for Matthew Greenhawt, MD, MBA, MSc, Chief Medical Officer of Aquestive Therapeutics (the “Company”), under the Company’s 2022 Equity Inducement Plan. The inducement grant was approved by the Company’s Compensation Committee. Under the Company’s 2022 Equity Inducement Plan, Dr. Greenhawt will receive an equity award of 75,000 Restricted Stock Units (the “Inducement RSUs”) and an equity award of 50,000 non-qualified common stock options (the “Inducement Options”), each award to be granted on March 9, 2026, which is the second full trading date following the date of the Company’s public release of annual financial results on March 5, 2026. The Inducement RSUs and the Inducement Options will vest 25% after each of the first and second anniversaries of the grant date, and 50% on the third anniversary of the grant date, subject to continued employment through the applicable grant date. The Inducement Options will have a term of ten years and an exercise price per share equal to the closing price of Aquestive’s common stock, par value $0.001 per share, on the Nasdaq Global Market on March 9, 2026, the scheduled grant date of the award. The Inducement RSUs and the Inducement Options are being granted in reliance on the employment inducement exemption provided under Nasdaq Listing Rule 5635(c)(4), and these awards were approved by the independent Compensation Committee of the Board of Directors of the Company as a material inducement for Dr. Greenhawt’s acceptance of employment with Aquestive. The Inducement RSUs and the Inducement Options were granted outside of the Company’s 2018 Equity Incentive Plan. About Aquestive Therapeutics, Inc. Aquestive is a pharmaceutical ...

Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026 Cash and Securities of $219.8 Million as of Year-End Supports Ongoing Clinical Execution CARLSBAD, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported fourth quarter and full year 2025 financial results and highlighted business updates and upcoming milestones across its GeneTAC® portfolio. “The fourth quarter capped a year of strong execution and meaningful progress across our GeneTAC® portfolio,” said Pratik Shah, Ph.D., chairperson and chief executive officer of Design Therapeutics. “We enter 2026 with three clinical programs advancing toward important milestones, including the planned initiation of patient dosing in our Phase 1 trial of DT-818 in DM1 in the first half of the year and anticipated data from DT-216P2 in FA and DT-168 in FECD in the second half of 2026. Together, these anticipated milestones position us for continued execution of our strategy to build a diversified set of clinical proof-of-concept opportunities for genetic diseases with significant unmet needs.” Corporate Highlights Friedreich Ataxia (FA): Design continues to dose FA patients in its RESTORE-FA Phase 1/2 MAD trial and anticipates providing an update on the effect of DT-216P2 on endogenous frataxin levels following 12 weeks of dosing in the second half of 2026. Fuchs Endothelial Corneal Dystrophy (FECD): A Phase 2 biomarker trial of DT-168 is ongoing to evaluate safety, tolerability and corneal endothelium biomarkers in FECD patients who are scheduled for corneal transplant surgery, with data anticipated in the second half of 2026. Myotonic Dystrophy Type-1 (DM1): Design expects to begin dosing DM1 patients in its Phase 1 multiple-ascending dose (MAD) trial of DT-818, a GeneTAC ® small molecule designed to selec...

Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026 Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026 Lorigerlimab Phase 2 LINNET study update in mid-2026 IND submission for MGC030, a first-in-class TOP1i-based ADC, on track for 3Q 2026 Cash, cash equivalents and marketable securities of $189.9 million as of December 31, 2025; cash runway guidance remains into late 2027 ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress, reported financial results for the year ended December 31, 2025, and highlighted anticipated data disclosure timelines for its product pipeline. “I am excited about MacroGenics' future prospects, and am inspired by the commitment of our employees over the past few quarters to sharpen our focus and advance our strategic priorities," said Eric Risser, President and CEO of MacroGenics. "Looking ahead, we anticipate several important milestones in 2026, including initial clinical data from the Phase 1 studies of MGC026 and MGC028, and from the LINNET study of lorigerlimab. Additionally, we plan to submit an IND for MGC030, a first-in-class topoisomerase I inhibitor-based ADC. Finally, with cash runway into late 2027, we believe we are well positioned to execute on our plan and drive meaningful value for our shareholders." Corporate Progress and Anticipated Milestones Innovative ADC Pipeline MacroGenics is developing potential best-in-class or first-in-class antibody-drug conjugates (ADCs) that leverage its protein engineering expertise and incorporate potent glycan-linked exatecan payloads designed to enable an expanded therapeutic window. The proprietary drug-linker platform is licensed from Synaffix B.V., a Lonza company. MacroGenics' two clinical-stage ADC programs, MGC026 and MGC028, have demonstrated acceptab...

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 - - Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody supports sustained brain exposure profile - - Ended 2025 with cash position of $202 million, expected to maintain runway into 2028 - LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported fourth quarter and full year 2025 financial and operating results. “Building on our pipeline progress in 2025, Voyager expects 2026 to be a pivotal year defined by three pillars of value creation: data on tau-targeting assets for Alzheimer’s disease, clinical entry for our novel I.V.-delivered neuro gene therapies, and advancement of our nonviral delivery platform, Voyager NeuroShuttle,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “With a strong cash position that is expected to provide runway into 2028, I believe Voyager is poised to execute across multiple clinical programs, further validate our platforms, and build a foundation for long-term shareholder value.” Fourth Quarter 2025 and Recent Highlights Pipeline updates: VY1706 (tau-silencing gene therapy): Voyager expects completion of a good laboratory practice (GLP) toxicology study in Q1 2026, investigational new drug (IND) application submission in Q2 2026, and first-in-human dosing in H2 2026. Following a pre-IND communication with U.S. Food and Drug Administration (FDA) in Q1 2025, Voyager completed a Type C communication with FDA in Q1 2026 and believes there to be a path to IND. VY7523 (anti-tau antibody): Multiple ascending dose (MAD) clinical trial in Alzheimer’s disease (AD) completed enrollment in Q4 2025. Tau positron emission tomography (PET)...

ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2025. “The past year saw tremendous progress with significant regulatory approvals globally, advancement of a broad pipeline of innovations, and revenue growth of over 20%. I’m proud of what our team has accomplished and excited for the year ahead,” said David Fischel, Chairman and CEO. “The highlight of the past year was achieving regulatory approvals in the United States and Europe for the GenesisX robot, MAGiC ablation catheter, and MAGiC Sweep high density mapping catheter. This core product portfolio serves as a foundation for significant commercial growth as the only robotic technology in the attractive electrophysiology market.” “The commercial contribution from these new products was modest in 2025 as we worked through challenges in ramping manufacturing of MAGiC and GenesisX. Our primary goals this year are to demonstrate the commercial success of these products, ramp manufacturing substantially, and progress a robust pipeline of additional innovations. These are being advanced in a methodical and financially prudent fashion.” Stereotaxis is focused on four key milestones this year: GenesisX Robot – Establish at least five active GenesisX programs with global Electrophysiology key opinion leaders and demonstrate the accessibility of GenesisX with rapid installations in existing labs. MAGiC & MAGiC Sweep Catheters – Ramp manufacturing of MAGiC to five hundred catheters a month by year end, transition Stereotaxis’ electrophysiology customers to MAGiC and MAGiC Sweep, and launch MAGiC with Pulsed Field Ablation in Europe. Endovascular Robotics – Demonstrate a comprehensive strategy for technological leadership in robotics across interventional cardiology and neurointerventions. Synchrony Digital Surgery S...

塔斯社援引俄罗斯总统助理Yuri Ushakov的话报道称，俄罗斯总统弗拉基米尔·普京和美国总统唐纳德·特朗普通电话，讨论了伊朗冲突相关局势以及有关乌克兰的三方谈判。 此次通话“内容十分充实，毫无疑问将对两国今后在国际政治各领域的进一步工作具有实际意义”。 责任编辑：丁文武

We’ve been busy testing many new MacBooks, ranging from the new MacBook Air with the M5 processor that’s $1,099, going all the way up the $6,149 16-inch MacBook Pro with the M5 Max chip. While these computers are identical in design to last year’s models, they have some things in common: neither delivers a significant lead over their M4 counterparts, although their faster SSDs might be enough reason for folks with older laptops to consider upgrading. We’ll have full reviews of both laptops soon; in the meantime, here are the benchmarks. The biggest actual change: Apple claims that its 2026 models can deliver “up to 2x” the sustained read and write speeds of the M4 laptops. Our testing bore that out: the 4TB SSD in the 16-inch M5 Max MacBook Pro could sustain a 13.6GB/s read speed and an even higher 17.8GB/s write speed. That’s a 86 percent faster read speed and a 123 percent faster write speed than the 4TB drive on our M4 Max review unit. My colleague Antonio G. Di Benedetto saw similar results in the 2026 MacBook Air with the M5, as well as the M5-equipped MacBook Pro that we reviewed in late 2025 compared to its predecessor. Photo: Antonio G. Di Benedetto / The Verge Our review configuration of the 16-inch MacBook Pro comes with an M5 Max chip with 18 CPU cores and 40 GPU cores, 128GB of memory, and 4TB SSD. The M4 Max version we tested in late 2024 had 16 CPU cores and 40 GPU cores, but the same memory and storage allocations, which makes comparisons easy. Here’s where it gets interesting: the M4 Max’s 16 cores are split between 12 performance cores and 4 efficiency cores. But for the M5 generation, Apple introduced a third type of core: the super core, and it also redesigned its performance cores. The M5 Max has six super cores and 12 of the new performance cores, “optimized for power-efficient, multi-threaded workloads.” The efficiency cores aren’t gone — they’re still on the base M5 chip — but they’re not on the Pro or Max. In single-core CPU tests, the new su...

俄罗斯总统助理乌沙科夫9日表示，俄总统普京与美国总统特朗普通电话，讨论伊朗局势和乌克兰问题。普京就尽快结束围绕伊朗的战事提出多个建议。（新华社） 风险提示及免责条款 市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何意见、观点或结论是否符合其特定状况。据此投资，责任自负。

President Donald Trump said the US war on Iran could be ending soon, stating the operation is ahead of schedule. He told CBS the war is "very complete." Kailey Leinz reports. (Source: Bloomberg)

Apple's M5 Pro and M5 Max make deceptively large changes to how Apple's high-end laptop and desktop chips are built. We've already covered those changes in some depth , but in essence: The M5 Pro and M5 Max are no longer monolithic chips with all the CPU and GPU cores and everything else packed into a single silicon die. Using an "all-new Fusion Architecture" like the one used to combine two Max chips into a single Ultra chip, Apple now splits the CPU cores (and other things) into one piece of silicon, and the GPU cores (and other things) into another piece of silicon. These two dies are then packaged together into one chip. M5 Pro and M5 Max both use the same 18-core CPU die, but Pro uses a 20-core GPU die, and Max gets a 40-core GPU die. (Because the memory controller is also part of the GPU die, the Max chip still offers more memory bandwidth and supports higher memory configurations than the Pro one does.) Read full article Comments

纳斯达克金龙中国指数收涨1.76%，报7083.84点。 热门中概股里，小鹏初步收涨6.4%，比亚迪涨6%，美团涨5.7%，理想、蔚来涨超3.8%，百度涨2.9%，腾讯涨2.4%，阿里巴巴涨1.4%，网易跌0.1%，文远知行跌1.4%。 ETF中，中国科技指数ETF（CQQQ）收涨3.01%，中概互联网指数ETF（KWEB）收涨2.79%。 德银嘉实沪深300指数ETF（ASHR）收涨1.06%，XtrackersHarvest中证50（ASHS）收涨0.81%。 风险提示及免责条款 市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何意见、观点或结论是否符合其特定状况。据此投资，责任自负。

Companies in southern China are feeling growing confidence in the state of US-China relations and are reinvesting cautiously in the country, according to a survey by a US business lobby group. The American Chamber of Commerce in South China (AmCham South China) – a mix of foreign and domestic firms – generally expects bilateral ties to stabilise in the year ahead, but is also adapting to geopolitical friction as China shifts from assembling Western goods to supplying industrial parts to emerging markets, the report found. A survey of more than 400 companies – conducted in late 2025 – found that 39 per cent of respondents expressed a positive outlook on the future of US-China relations, up 14 percentage points from 2024, the chamber said in the study released on Tuesday. Advertisement “Because of the continuing conversations between China and America, the future of US-China trade through 2026 will be characterised by a ‘tactical truce’ – slowing but not stopping economic decoupling – with bilateral trade increasingly focused on non-sensitive sectors,” said Harley Seyedin, chairman and president of AmCham South China, at a press conference the same day. The finding came ahead of US President Donald Trump’s expected trip to China at the end of March, which will be the first such visit by an American leader in nine years if it goes ahead. Advertisement Of the 426 respondents to the AmCham South China survey, 32 per cent were from the United States, 28 per cent from mainland China, 12 per cent from Europe, 18 per cent from Hong Kong or Macau, with the remainder coming from several other regions.

The following companies are expected to report earnings prior to market open on 03/10/2026. Visit our Earnings Calendar for a full list of expected earnings releases. BioNTech SE (BNTX)is reporting for the quarter ending December 31, 2025. The biomedical (gene) company's consensus earnings per share forecast from the 4 analysts that follow the stock is $-0.22. This value represents a 119.13% decrease compared to the same quarter last year. The last two quarters BNTX had negative earnings surprises; the latest report they missed by -118.67%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for BNTX is -26.36 vs. an industry ratio of -5.70. NIO Inc. (NIO)is reporting for the quarter ending December 31, 2025. The auto (foreign) company's consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.05. This value represents a 89.36% increase compared to the same quarter last year. Zacks Investment Research reports that the 2025 Price to Earnings ratio for NIO is -4.55 vs. an industry ratio of 14.70. Uranium Energy Corp. (UEC)is reporting for the quarter ending January 31, 2026. The consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.06. UEC reported earnings of $-0.01 per share for the same quarter a year ago; representing a a increase of 500.00%.Legend Biotech Corporation (LEGN)is reporting for the quarter ending December 31, 2025. The biomedical (gene) company's consensus earnings per share forecast from the 7 analysts that follow the stock is $-0.17. This value represents a 13.33% decrease compared to the same quarter last year. LEGN missed the consensus earnings per share in the 2nd calendar quarter of 2025 by -54.55%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for LEGN is -11.86 vs. an industry ratio of -5.70. ABM Industries Incorporated (ABM)is reporting for the quarter ending January 31, 2026. The business services company's consensus earnings per shar...

Abbey theatre, Dublin Director Tom Creed brings this 1926 political classic into the present, with a tremendous cast navigating the tonal switch from comedy into tragedy Marking the centenary of the premiere of Seán O’Casey’s potent political drama, the Abbey’s latest production opens a door to looser, more experimental ways of staging it. Frequently produced in recent years , the tragi-comic work that caused a riot in 1926 is now embedded in the Irish theatre canon. It is set among Dublin tenement dwellers in the run-up to the Easter Rising of 1916 , and O’Casey’s characters are caught up in events beyond their control. Try as she might, the newly married Nora Clitheroe (Kate Gilmore) can’t persuade her husband Jack (Eimhin Fitzgerald Doherty) to stay home rather than joining an Irish Citizen Army rally. Nor can she keep the outside world at bay, with her neighbours, the absurdly morbid Mrs Gogan (Kate Stanley Brennan) and hard-drinking Unionist Bessie Burgess (Mary Murray) bursting in constantly, with no privacy possible. At Abbey theatre, Dublin , until 30 April Continue reading...

is a senior reviewer covering TVs and audio. He has over 20 years experience in AV, and has previously been on staff at Digital Trends and Reviewed. It’s been almost exactly four years since Apple released the 5K Studio Display that so many wanted, even if it didn’t really deliver as a high-end display. Apple has now revamped the Studio Display lineup, sort of, with another Studio Display and the Studio Display XDR. They’re both 27-inch 5K (5,120 x 2,880) displays with the 12MP Center Stage camera — which is a significant upgrade over the old camera and looks clear with minimal noise — and six-speaker spatial audio system built in, and two Thunderbolt 5 ports alongside two USB-C. The new Studio Display looks like the same panel from four years ago, just with the upgraded camera, speakers, and ports. It has the same peak brightness of 600 nits and is only capable of SDR, like the old model. Even the pricing is the same, at $1,599, or an extra $300 if you include nano-texture glass. Now you can also add a tilt- and height-adjustable stand — for an extra $400. Cool, I guess. The Studio Display XDR, on the other hand, is far more interesting. It’s replacing the 32-inch 6K Pro Display XDR, which cost $5,000 and was released in 2020. The Studio Display XDR uses a completely new mini-LED display with 2,304 local dimming zones, has a max brightness of 2,000 nits, has adaptive refresh rate up to 120Hz (although you’ll need a newer Mac to support it), and supports HDR. It has a bunch of accurate reference picture modes, native support for both P3 and Adobe RGB color spaces, and two general picture modes calibrated to Apple CMF 2026 — a new display standard Apple has developed. It’s a lot of attractive specs for creative professionals, but it also has a very Apple typical starting price of $3,299 — twice as much as the regular Studio Display. It had better be good. The Studio Display XDR’s panel is the most advanced we’ve seen on a standalone Apple monitor, utilizing mini-LEDs...

Oracle Corporation Class Action: Levi & Korsinsky Reminds GlobeNewswire

道瓊斯工業平均指數收報47,740點，升239點。 標準普爾五百指數收報6,795點，升55點。

Source: Bloomberg, 11:49

Bloomberg’s Caroline Hyde and Ed Ludlow discuss the impact of the ongoing conflict in the Middle East. Plus, Oracle and OpenAI scrap plans to expand a flagship data center project in Texas. And, Anthropic sues the US Department of Defense after the government labeled the AI firm a supply chain risk. (Source: Bloomberg)

Razvan25/iStock via Getty Images Private equity firm Advent International is exploring a potential sale of its Ultra Maritime business that could value the naval defense company at more than £3 billion ($4 billion), Bloomberg News reported Monday, citing people familiar with the discussions. Advent has begun speaking with banks about a possible transaction and may launch a sale process in the coming months, the people said. The asset could draw interest from both defense contractors and private equity firms, with valuations based on projected earnings and comparisons with similar companies. The deliberations remain at an early stage and Advent has not yet committed to a formal sale process. The firm could ultimately decide to retain the business, the people said. A representative for Advent declined to comment, while Ultra Maritime did not immediately respond to requests for comment. Ultra Maritime specializes in technologies used in anti-submarine warfare, including sonar systems, sonobuoys and torpedo countermeasures designed to detect and counter underwater threats. The company provides equipment to naval forces in countries including the United States, Canada, the United Kingdom and Australia. Advent acquired the business as part of a broader effort to reshape defense assets purchased in recent years. The firm bought British aerospace and defense group Cobham in a £4 billion deal in 2020 and later acquired Ultra Electronics Holdings. Since then, Advent has sold off several divisions from those companies. In June, Advent agreed to sell Ultra PCS, a unit that produces systems used to release missiles from aircraft, to Eaton ( ETN ) for about $1.55 billion. A potential divestiture of Ultra Maritime comes as investor interest in defense companies rises amid growing geopolitical tensions. Governments across Europe have pledged significant spending increases to strengthen military capabilities and reduce reliance on U.S. defense suppliers. Naval security has also draw...

Many fintech stocks fizzled out over the past year amid macro uncertainties that drove investors away from the high-growth sector. But over the long term, the fintech sector should continue to flourish as more consumers shift all of their banking services online. Two companies that will profit from that secular expansion are Affirm (AFRM 1.66%) and Chime (CHYM +1.78%). Let's see what these two fintech companies do, and why they might turn a modest $500 investment into thousands of dollars over the next few years. Affirm's BNPL business is booming Affirm provides buy now, pay later (BNPL) services to younger and lower-income consumers who don't use credit cards. It splits these "microloans" into four or more recurring payments, and it doesn't charge any compound interest or hidden fees. Affirm is also an appealing platform for merchants, since its fees are generally lower than credit card swipe fees. Expand NASDAQ : AFRM Affirm Today's Change ( -1.66 %) $ -0.86 Current Price $ 50.84 Key Data Points Market Cap $17B Day's Range $ 49.19 - $ 51.36 52wk Range $ 30.90 - $ 100.00 Volume 220K Avg Vol 6.3M Gross Margin 76.58 % Affirm ended its latest quarter with 25.8 million active consumers, who made an average of 6.4 transactions each, and 478,000 active merchants. That's up from 21 million active consumers, 5.3 average transactions, and 337,000 active merchants a year earlier. From fiscal 2025 (which ended last June) to fiscal 2028, analysts expect its revenue and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) to grow at CAGRs of 26% and 132%, respectively, as the BNPL market expands. Yet with an enterprise value of $18 billion, it still looks like a bargain at 16 times this year's adjusted EBITDA. Chime is challenging conventional banks Chime's platform provides fee-free checking and savings accounts with overdraft protection, early pay features, and other financial services. It also issues a Visa (V 0.41%) debit card with fee-free acce...

Key Points Affirm’s BNPL services are still locking in more customers and merchants. Chime will continue to draw lower-income members away from conventional banks. 10 stocks we like better than Affirm › Many fintech stocks fizzled out over the past year amid macro uncertainties that drove investors away from the high-growth sector. But over the long term, the fintech sector should continue to flourish as more consumers shift all of their banking services online. Two companies that will profit from that secular expansion are Affirm (NASDAQ: AFRM) and Chime (NASDAQ: CHYM). Let's see what these two fintech companies do, and why they might turn a modest $500 investment into thousands of dollars over the next few years. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Affirm's BNPL business is booming Affirm provides buy now, pay later (BNPL) services to younger and lower-income consumers who don't use credit cards. It splits these "microloans" into four or more recurring payments, and it doesn't charge any compound interest or hidden fees. Affirm is also an appealing platform for merchants, since its fees are generally lower than credit card swipe fees. Affirm ended its latest quarter with 25.8 million active consumers, who made an average of 6.4 transactions each, and 478,000 active merchants. That's up from 21 million active consumers, 5.3 average transactions, and 337,000 active merchants a year earlier. From fiscal 2025 (which ended last June) to fiscal 2028, analysts expect its revenue and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) to grow at CAGRs of 26% and 132%, respectively, as the BNPL market expands. Yet with an enterprise value of $18 billion, it still looks like a bargain at 16 times this year's adjusted EBITDA. Chime is challenging conventional banks...